RECRUITING

Imaging Studies in Corticobasal Syndrome

Description

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Conditions

Cortico Basal DegenerationCorticobasal SyndromeCorticobasal Syndrome(CBS)Corticobasal DegenerationCorticobasal Degeneration (CBD)Corticobasal Syndrome (CBS)
Talk to us

Related Conditions:

Cortico Basal DegenerationCorticobasal SyndromeCorticobasal Syndrome(CBS)Corticobasal DegenerationCorticobasal Degeneration (CBD)Corticobasal Syndrome (CBS)

Study Overview

On this page

Study Details

Study overview

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome

Imaging Studies in Corticobasal Syndrome

Condition
Cortico Basal Degeneration
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older
  • * Meet possible or probable CBS criteria
  • * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
  • * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
  • * Subjects will be excluded if they have a mutation in the progranulin gene
  • * Subjects will excluded if they have received anti-Aβ therapy
  • * Women who are pregnant will be excluded
  • * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)
  • * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Jennifer Whitwell,

Jennifer Whitwell, Ph.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2031-03-30